Surreal illustration symbolizing stem cell transplantation with medical personnel caring for a patient.

Navigating Day Zero: A Comprehensive Guide to Adverse Reactions in Stem Cell Transplants

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 5 min read.

"Everything you need to know about recognizing and managing adverse reactions during hematopoietic stem cell transplantation, ensuring patient safety and comfort."


Hematopoietic stem cell transplantation (HSCT) is a powerful medical procedure used to treat various malignant and non-malignant disorders of the hematopoietic system. This treatment involves subjecting the patient to chemotherapy and/or radiotherapy, followed by the infusion of hematopoietic stem cells (HSCs). While HSCT offers the potential for long-term remission or cure, it is also associated with significant risks, particularly during the infusion process itself.

The day of HSC infusion, often referred to as "Day Zero," is a critical point in the transplantation process. During this phase, the patient can experience a range of adverse reactions, varying in severity from mild discomfort to life-threatening complications. These reactions can stem from various factors, including the characteristics of the infused cells, the presence of cryoprotective agents like Dimethyl Sulfoxide (DMSO), and the patient's underlying health condition.

Therefore, understanding the potential adverse reactions associated with HSC infusion on Day Zero is crucial for healthcare professionals, especially nurses, who play a pivotal role in patient care during this period. By being aware of these reactions, nurses can implement preventive measures, promptly identify complications, and initiate appropriate interventions to ensure patient safety and optimize treatment outcomes.

AI Search Multiple angles on this topic

The Hematopoietic Foundation

Hematopoiesis is the process of blood cell formation, originating from hematopoietic stem cells located in the bone marrow of the femurs, pelvis, ribs, sternum, and other bones. These stem cells can differentiate into all types of mature blood cells, including red blood cells, white blood cells, and platelets. The hematopoietic system therefore supports oxygen transport, immune defense, and wound sealing, although the supplied sources do not provide specific statistics on adverse reactions in stem cell transplants.

Clinical Methods and Limits

Clinical approaches to stem cell transplantation generally require careful evaluation of the procedure, its expected benefits, and possible adverse reactions. However, the available source material does not specify accepted methods, comparative protocols, or quantified limitations. Any discussion of standard practice should therefore be treated as general context rather than a source-supported clinical recommendation.

Foundations of Transplantation

The scientific foundation for stem cell transplantation rests on recognizing that blood cells arise from hematopoietic stem cells. This understanding provides a framework for considering how transplanted cells may contribute to blood-cell formation. The supplied material does not identify particular historical milestones, dates, or foundational discoveries, so a detailed chronology cannot be established here.

Decoding Adverse Reactions: What to Expect on Day Zero

Surreal illustration symbolizing stem cell transplantation with medical personnel caring for a patient.

Adverse reactions during HSC infusion can manifest in various ways, affecting different organ systems. A recent integrative review of the literature identified the most common and significant adverse reactions experienced by patients on Day Zero of hematopoietic stem cell transplantation. This review analyzed data from multiple studies to provide a comprehensive overview of potential complications.

The studies included in the review utilized different classification systems to categorize the severity and type of adverse reactions. Some studies classified reactions as mild, moderate, severe, or life-threatening, while others categorized them by the affected organ system, such as cardiovascular, respiratory, or gastrointestinal. Despite the variations in classification, the review identified several consistent patterns in the types and frequencies of adverse reactions.

  • Nausea and Emesis: Consistently reported as the most frequent adverse reactions across multiple studies. These symptoms are often attributed to the toxicity of DMSO, a cryoprotective agent used to preserve HSCs during freezing.
  • Cardiovascular Issues: Common cardiovascular reactions include bradycardia (slow heart rate), tachycardia (fast heart rate), hypertension (high blood pressure), and hypotension (low blood pressure). These reactions can be triggered by the infusion process itself or by the release of cytokines.
  • Respiratory Distress: Respiratory complications such as dyspnea (shortness of breath), hypoxia (low oxygen levels), and throat irritation were also frequently observed. These reactions may be related to allergic responses or volume overload.
  • Other Reactions: Additional adverse reactions reported in the review include chills, fever, flushing, headache, abdominal pain, and allergic reactions. The severity and frequency of these reactions varied depending on the study and the patient population.
AI Search Multiple angles on this topic

Current Research Boundaries

Research on adverse reactions in stem cell transplantation continues to examine how treatment affects patients and blood-cell recovery. The supplied source material does not identify recent studies, reviews, investigators, or research findings specific to this topic. Conclusions about the latest evidence should therefore remain provisional until current clinical literature is examined.

Uncertainty and Treatment Risk

Stem cell transplantation can involve both intended therapeutic effects and unwanted reactions, making outcomes important to evaluate from more than one perspective. The available material does not document specific failures, counterarguments, or rates of unsuccessful treatment. It is therefore not possible from these sources alone to attribute particular risks or outcomes to a defined transplant approach.

Comparing Clinical Approaches

Comparative analysis of stem cell transplant approaches would require consistent information about procedures, patient groups, outcomes, and adverse reactions. None of those comparative data are provided in the source material for this subsection. Any ranking of methods or claims that one approach is safer would consequently be unsupported here.

The integrative review also highlighted the importance of patient and infusion-related factors in the occurrence of adverse reactions. Factors such as the volume of the infused product, the number of total nucleated cells and granulocytes, and the patient's age, weight, and underlying health condition can all influence the risk and severity of complications. Understanding these risk factors can help healthcare professionals to identify patients who may be at higher risk and to tailor their management strategies accordingly.

Empowering Nurses: Minimizing Risks and Maximizing Patient Comfort

Given the potential for adverse reactions during HSC infusion, nurses play a crucial role in ensuring patient safety and optimizing treatment outcomes. By understanding the risk factors, recognizing the signs and symptoms of adverse reactions, and implementing appropriate interventions, nurses can help to minimize complications and improve the overall patient experience. Future research should focus on developing evidence-based protocols for the prevention and management of adverse reactions during HSC infusion. Additionally, studies are needed to evaluate the effectiveness of different interventions, such as premedication strategies, DMSO reduction techniques, and supportive care measures, in reducing the incidence and severity of complications. By continuing to advance our knowledge and improve our clinical practices, we can make HSC transplantation safer and more effective for patients.

AI Search Multiple angles on this topic

Interpreting the Evidence

A cautious synthesis should recognize that hematopoietic stem cells are central to the formation of mature blood cells while avoiding conclusions not established by the available evidence. The supplied material does not include expert commentary on adverse reactions in stem cell transplantation. Clinical interpretation should therefore remain individualized and rely on appropriate medical assessment.

Future Directions

Future work may seek to improve understanding of how stem cell transplantation affects blood-cell formation and patient responses. The available source material does not identify specific emerging technologies, research programs, or predicted milestones. Claims about particular next frontiers would therefore require additional, up-to-date sources.

System-Level Considerations

Stem cell transplantation sits within the broader biological system responsible for producing red blood cells, white blood cells, and platelets. The supplied material does not address healthcare access, costs, infrastructure, policy, or other systemic challenges surrounding transplantation. Those issues should not be inferred from the biological descriptions alone.

Patient-Centered Impact

Because the hematopoietic system supports oxygen transport, immune defense, and wound sealing, disturbances affecting blood-cell production can have important human consequences. The supplied sources do not describe patients' experiences, quality-of-life outcomes, or lived experiences of adverse reactions after transplantation. A complete account of real-world impact would therefore need patient-centered and clinical evidence beyond the material provided.

Grade 2 or higher reactions across transplant types

  • 37.7% vs 20.9% vs 19.3%Grade 2 or higher adverse events were reported most often in allo-BMTs without DMSO in the product: 37.7%, compared with 20.9% in auto-/allo-PBSCTs and 19.3% in allo-CBTs, which were typically cryopreserved with DMSO.[1]

How these findings compare across products and evidence

Hemoglobinuria can accompany serious complications, including acute renal failure and disseminated intravascular coagulation associated with hemolysis; monitoring urine output and fluid balance can support early detection. This describes a monitoring rationale, not evidence that monitoring prevents those complications.[2]

Interpretation is constrained because conditioning treatment and other transplant contents can also contribute to side effects, while clinical-trial adverse-event rates may not translate directly across trials or to practice. The cited nursing-care source also identifies a scarcity of nursing studies on Day Zero care, limiting the evidence base for that specific aspect of care.[2] [3] [4]

Questions the infusion evidence leaves open

  • Which product or patient characteristics account for the higher incidence in allo-BMTs, given that DMSO exposure alone does not explain the observed pattern?[1] [3]
  • How consistently do infusion-related adverse events occur across fresh and cryopreserved products when surveillance captures the different cellular and plasma components?[1]
  • What evidence would establish whether Day Zero nursing practices change recognition of hemoglobinuria or its associated complications?[2]

Terms used in infusion evidence

DMSO
A substance included in cryopreserved HSC products and associated with toxicity attributed to some infusion-related adverse events.[1]

Sources

  1. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study | OpenAlex (openalex.org)
  2. Brasil - PROTOCOL OF NURSING CARE ON ZERO DAY OF THE TRANSPLANTATION OF HEMATOPOETIC STEM CELLS: COLLECTIVE CONSTRUCTION PROTOCOL OF NURSING CARE ON ZERO DAY OF THE TRANSPLANTATION OF HEMATOPOETIC STE (new.scielo.br)
  3. Dimethyl sulfoxide in cryopreserved mesenchymal stromal cell therapy products: is there a safety risk to patients? (pmc.ncbi.nlm.nih.gov)
  4. Package Insert - HPC, Cord Blood - MD Anderson Cord Blood Bank (www.fda.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are the most common adverse reactions observed during hematopoietic stem cell transplantation (HSCT) on Day Zero, and what factors contribute to these reactions?

The most frequently reported adverse reactions during HSCT on Day Zero include nausea and emesis, cardiovascular issues such as bradycardia, tachycardia, hypertension, and hypotension, and respiratory distress like dyspnea and hypoxia. These reactions are often attributed to factors such as the toxicity of Dimethyl Sulfoxide (DMSO), a cryoprotective agent used to preserve hematopoietic stem cells (HSCs), the release of cytokines during the infusion process, and patient-related factors like age, weight, and underlying health conditions. The volume of the infused product and the number of total nucleated cells and granulocytes can also influence the risk and severity of these complications.

2

How do cardiovascular adverse reactions manifest during hematopoietic stem cell infusions, and what are the potential triggers?

Cardiovascular reactions during hematopoietic stem cell infusions can manifest as bradycardia (slow heart rate), tachycardia (fast heart rate), hypertension (high blood pressure), and hypotension (low blood pressure). These reactions can be triggered by the infusion process itself or by the release of cytokines. Understanding these triggers is crucial for healthcare professionals to promptly identify and manage cardiovascular complications, ensuring patient safety during HSCT.

3

Why is Dimethyl Sulfoxide (DMSO) a significant concern during hematopoietic stem cell infusions, and what adverse reactions are associated with its use?

Dimethyl Sulfoxide (DMSO) is a cryoprotective agent used to preserve hematopoietic stem cells (HSCs) during freezing. However, it is also associated with several adverse reactions, most notably nausea and emesis. The toxicity of DMSO contributes significantly to these symptoms, making it a primary concern during HSC infusions. Strategies to mitigate DMSO-related adverse reactions are essential for improving patient comfort and overall treatment outcomes.

4

What role do nurses play in minimizing the risks and maximizing patient comfort during hematopoietic stem cell infusions on Day Zero?

Nurses play a critical role in ensuring patient safety and optimizing treatment outcomes during hematopoietic stem cell infusions. By understanding the risk factors, recognizing the signs and symptoms of adverse reactions, and implementing appropriate interventions, nurses can help minimize complications and improve the overall patient experience. Their responsibilities include monitoring vital signs, administering premedications, managing infusion rates, and providing supportive care to address symptoms like nausea, fever, and respiratory distress. Future research should focus on developing evidence-based protocols for nurses to prevent and manage adverse reactions effectively.

5

Beyond nausea, cardiovascular issues, and respiratory distress, what other adverse reactions can occur during hematopoietic stem cell transplantation (HSCT) on Day Zero, and what factors influence their severity?

In addition to nausea, cardiovascular issues, and respiratory distress, other adverse reactions reported during HSCT on Day Zero include chills, fever, flushing, headache, abdominal pain, and allergic reactions. The severity and frequency of these reactions vary depending on factors such as the study methodology, patient population, and individual patient characteristics. Patient-related factors like age, weight, and underlying health conditions, as well as infusion-related factors like the volume of the infused product and the number of total nucleated cells and granulocytes, can all influence the risk and severity of these complications. A comprehensive understanding of these factors is essential for tailoring management strategies and optimizing patient outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.